{"id":383686,"date":"2023-12-15T11:10:00","date_gmt":"2023-12-15T16:10:00","guid":{"rendered":"https:\/\/platohealth.ai\/fda-widens-use-of-cancer-drug-merck-acquired-for-1b\/"},"modified":"2023-12-15T18:30:20","modified_gmt":"2023-12-15T23:30:20","slug":"fda-widens-use-of-cancer-drug-merck-acquired-for-1b","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/fda-widens-use-of-cancer-drug-merck-acquired-for-1b\/","title":{"rendered":"FDA widens use of cancer drug Merck acquired for $1B","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"<div><img decoding=\"async\" src=\"https:\/\/platohealth.ai\/wp-content\/uploads\/2023\/12\/fda-widens-use-of-cancer-drug-merck-acquired-for-1b.jpg\" class=\"ff-og-image-inserted\"><\/div>\n<h3>Dive Brief:<\/h3>\n<ul>\n<li>The Food and Drug Administration on Thursday broadened use of a drug <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-advanced-renal-cell-carcinoma\">Merck &amp; Co. acquired in a $1 billion buyout<\/a>\u00a0four years ago, clearing Welireg for use in people whose kidney tumors have progressed following treatment with two other types of medicines.\u00a0<\/li>\n<li>Approval was based on a trial <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.biopharmadive.com\/news\/merck-kidney-cancer-drug-results-peloton\/691285\/\">that compared Welireg to an older therapy<\/a>\u00a0called everolimus. Merck\u2019s drug reduced the risk of cancer progression or death by 25% compared with everolimus and shrank or eliminated tumors in 22% of people who received it. Welireg hasn\u2019t yet proven it can help kidney cancer patients live longer, however.\u00a0<\/li>\n<li>Merck inherited Welireg when it bought <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.biopharmadive.com\/news\/merck-peloton-kidney-cancer-deal-acquisition\/555259\/\">biotechnology company Peloton Therapeutics<\/a>. Since then, the drug\u2019s been cleared for use in a rare condition called von Hippel-Lindau disease and now kidney cancer. Merck is studying its potential in other settings as well.<\/li>\n<\/ul>\n<h3>Dive Insight:<\/h3>\n<p>Welireg is a new kind of cancer drug, blocking production of a protein called HIF-2 alpha that is implicated in cancer growth. Merck believes the treatment could become a blockbuster medicine and future growth driver, though it has a long way to go, generating about $146 million in sales through the first nine months of 2023.\u00a0<\/p>\n<p>That number could rise substantially with its new approval in kidney cancer, a larger market opportunity than the rare condition for which it was first approved. The FDA has specifically cleared Welireg for use in kidney cancer patients after they\u2019ve received an immunotherapy, like Merck\u2019s Keytruda, and a type of targeted medicine.\u00a0<\/p>\n<p>The approval was granted quickly, only months after Merck in August <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.biopharmadive.com\/news\/merck-kidney-cancer-drug-results-peloton\/691285\/\">reported positive interim results from a pivotal trial.<\/a>\u00a0Yet there are questions about the benefits Welireg provides. At a medical meeting in October, Merck revealed that, while Welireg\u2019s response rates and effects on cancer progression had widened, it hasn\u2019t provided a survival benefit. That finding has led some oncologists to <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.oncologypipeline.com\/apexonco\/esmo-2023-not-so-fast-welireg\">question its value<\/a>.<\/p>\n<p>Its impact on cancer\u2019s march has also been modest, with study results showing it helped patients live a median of 5.6 months before their disease got worse or death, comparable to everolimus. The 25% relative risk reduction measured for Welireg over everolimus is the result of delayed progression in patients who surpassed the 5.6-month median, according to the <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.merck.com\/product\/usa\/pi_circulars\/w\/welireg\/welireg_pi.pdf\">drug\u2019s prescribing information<\/a>.<\/p>\n<p>Still, the drug will fill a gap, as it\u2019s the first specifically approved for its particular patient group. It\u2019s also provided a blueprint for others in development. Arcus Biosciences has a <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/arcusbio.com\/our-science\/pipeline\/\">similar drug<\/a> in testing against advanced tumors, including kidney cancers.\u00a0<\/p>\n<ul class=\"plato-post-bottom-links\">\n<li class=\"plato-post-bottom-link-amplifi\">SEO Powered Content &amp; PR Distribution. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.amplifipr.com\">Get Amplified Today.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platodata-network\">PlatoData.Network Vertical Generative Ai. Empower Yourself. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platodata.network\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoaistream\">PlatoAiStream. Web3 Intelligence. Knowledge Amplified. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoaistream.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoesg\">PlatoESG. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/carbon\/\">Carbon,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/cleantech\/\">CleanTech,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/energy\/\">Energy,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/environment\/\">Environment,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/solar\/\">Solar,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/waste-management\/\">Waste Management.<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platohealth\">PlatoHealth. Biotech and Clinical Trials Intelligence. <a href=\"https:\/\/platohealth.ai\" target=\"_blank\" rel=\"noopener\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-source\"><span>Source:<\/span> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.biopharmadive.com\/news\/merck-welireg-fda-approval-kidney-cancer\/702661\/\">https:\/\/www.biopharmadive.com\/news\/merck-welireg-fda-approval-kidney-cancer\/702661\/<\/a><\/li>\n<\/ul>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"<p>Dive Brief: The Food and Drug Administration on Thursday broadened use of a drug Merck &amp; Co. acquired in a $1 billion buyout\u00a0four years ago, clearing Welireg for use in people whose kidney tumors have progressed following treatment with two other types of medicines.\u00a0 Approval was based on a trial that compared Welireg to an [&hellip;]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":383689,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/383686"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=383686"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/383686\/revisions"}],"predecessor-version":[{"id":383688,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/383686\/revisions\/383688"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/383689"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=383686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=383686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=383686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}